JP2017524715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524715A5 JP2017524715A5 JP2017507739A JP2017507739A JP2017524715A5 JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5 JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding portion
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1414270.7A GB201414270D0 (en) | 2014-08-12 | 2014-08-12 | Antibodies |
| GB1414270.7 | 2014-08-12 | ||
| GB201422614 | 2014-12-18 | ||
| GB1422614.6 | 2014-12-18 | ||
| GB1507541.9 | 2015-05-01 | ||
| GBGB1507541.9A GB201507541D0 (en) | 2015-05-01 | 2015-05-01 | Antibodies |
| PCT/EP2015/068598 WO2016023960A1 (en) | 2014-08-12 | 2015-08-12 | Combination therapies with anti cd40 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524715A JP2017524715A (ja) | 2017-08-31 |
| JP2017524715A5 true JP2017524715A5 (enExample) | 2018-09-27 |
| JP6654187B2 JP6654187B2 (ja) | 2020-02-26 |
Family
ID=53836090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507739A Active JP6654187B2 (ja) | 2014-08-12 | 2015-08-12 | 抗ｃｄ４０抗体を用いた併用療法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11149090B2 (enExample) |
| EP (3) | EP3552665A3 (enExample) |
| JP (1) | JP6654187B2 (enExample) |
| KR (1) | KR102443258B1 (enExample) |
| CN (3) | CN114099671A (enExample) |
| AU (1) | AU2015303164B2 (enExample) |
| CA (1) | CA2957146A1 (enExample) |
| CL (1) | CL2017000335A1 (enExample) |
| CO (1) | CO2017001317A2 (enExample) |
| CR (1) | CR20170096A (enExample) |
| DK (1) | DK3180087T3 (enExample) |
| EA (1) | EA201790339A1 (enExample) |
| EC (1) | ECSP17008984A (enExample) |
| ES (1) | ES2725463T3 (enExample) |
| IL (1) | IL250512B (enExample) |
| MA (1) | MA47472A (enExample) |
| MX (1) | MX382549B (enExample) |
| NI (1) | NI201700015A (enExample) |
| PE (1) | PE20170680A1 (enExample) |
| PH (1) | PH12017500229A1 (enExample) |
| SG (1) | SG11201701070WA (enExample) |
| SV (1) | SV2017005380A (enExample) |
| UA (1) | UA119783C2 (enExample) |
| WO (1) | WO2016023960A1 (enExample) |
| ZA (1) | ZA201701126B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
| DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| HRP20231392T1 (hr) | 2015-05-15 | 2024-04-26 | The General Hospital Corporation | Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| TW202216787A (zh) | 2015-11-18 | 2022-05-01 | 美商默沙東藥廠 | Pd1及／或 lag3結合劑 |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| EP3455262A4 (en) * | 2016-05-13 | 2020-04-08 | The General Hospital Corporation | ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EA201990293A1 (ru) | 2016-07-14 | 2019-07-31 | Генмаб А/С | Мультиспецифичные антитела против cd40 и cd137 |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| EP3532505A4 (en) | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| EP3534951A4 (en) * | 2016-11-02 | 2020-09-23 | Apexigen, Inc. | ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES |
| JP7304287B2 (ja) | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| EP3569616B1 (en) * | 2017-01-13 | 2021-09-29 | Taizhou Hanzhong Biopharmaceutics, Inc. | Monoclonal antibody against pd-1 and applications thereof |
| JP2020510673A (ja) * | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク，インコーポレーテツド | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 |
| CA3071217A1 (en) | 2017-08-31 | 2019-03-07 | Multimmune Gmbh | Hsp70 based combination therapy |
| BR112020018761A2 (pt) * | 2018-03-13 | 2020-12-29 | Hibercell, Inc. | Imunoterapia combinada com beta-glucano e agonista de cd40 |
| EP3807320A4 (en) * | 2018-06-12 | 2022-03-23 | BioNTech US Inc. | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| JP7155403B2 (ja) * | 2018-08-20 | 2022-10-18 | ファイザー・インク | 抗ｇｄｆ１５抗体、組成物および使用の方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020102739A1 (en) | 2018-11-15 | 2020-05-22 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| AU2019383548A1 (en) | 2018-11-23 | 2021-06-24 | Strike Pharma Ab | Bi-specific conjugates |
| EP3892634A4 (en) * | 2018-11-30 | 2022-11-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US20230174658A1 (en) * | 2019-05-28 | 2023-06-08 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd40 antibody |
| US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230055235A1 (en) * | 2019-12-27 | 2023-02-23 | Interoligo Corporation. | Anti-cancer immunotherapeutic composition for treating cancer |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022002065A1 (zh) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4415757A4 (en) * | 2021-10-15 | 2025-10-08 | Univ Rockefeller | COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER |
| CN118201636A (zh) * | 2021-10-26 | 2024-06-14 | 萨摩亚商柏沛生医股份有限公司 | 抗癌症及感染性疾病的组合疗法 |
| WO2023247050A1 (en) | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| ATE295882T1 (de) | 2000-12-12 | 2005-06-15 | Alligator Bioscience Ab | Eine methode zur in vitro molekularen evolution der proteinfunktion |
| ATE374214T1 (de) | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| ES2285118T5 (es) | 2002-05-17 | 2012-09-21 | Alligator Bioscience Ab | Un método para el desarrollo molecular in vitro de una función proteica. |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CA2564296A1 (en) | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| ATE485057T1 (de) | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| AU2009206506B2 (en) | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
| AU2009286247A1 (en) * | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| ES2581516T3 (es) * | 2009-09-16 | 2016-09-06 | The Chemours Company Fc, Llc | Aparato enfriador que contiene trans-1,1,1,4,4,4-hexafluoro-2-buteno y procedimientos para producir enfriamiento en él |
| GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| EA201600474A1 (ru) | 2013-12-20 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Комбинированная терапия с использованием антитела к ang2 и агониста cd40 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| MA53243A (fr) | 2015-04-17 | 2021-06-23 | Bristol Myers Squibb Co | Compositions comprenant une combinaison de ipilimumab et nivolumab |
| CN107810198B (zh) | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| CN107771184B (zh) | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | 针对cd40的抗体 |
| CA2990015A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
-
2015
- 2015-08-12 CA CA2957146A patent/CA2957146A1/en active Pending
- 2015-08-12 KR KR1020177005821A patent/KR102443258B1/ko active Active
- 2015-08-12 EP EP19161728.1A patent/EP3552665A3/en not_active Withdrawn
- 2015-08-12 MX MX2017001864A patent/MX382549B/es unknown
- 2015-08-12 PE PE2017000203A patent/PE20170680A1/es unknown
- 2015-08-12 ES ES15750051T patent/ES2725463T3/es active Active
- 2015-08-12 EA EA201790339A patent/EA201790339A1/ru unknown
- 2015-08-12 DK DK15750051.3T patent/DK3180087T3/da active
- 2015-08-12 UA UAA201701452A patent/UA119783C2/uk unknown
- 2015-08-12 SG SG11201701070WA patent/SG11201701070WA/en unknown
- 2015-08-12 CR CR20170096A patent/CR20170096A/es unknown
- 2015-08-12 MA MA047472A patent/MA47472A/fr unknown
- 2015-08-12 AU AU2015303164A patent/AU2015303164B2/en active Active
- 2015-08-12 CN CN202111420044.6A patent/CN114099671A/zh active Pending
- 2015-08-12 CN CN201580043161.1A patent/CN106573981A/zh active Pending
- 2015-08-12 EP EP25194883.2A patent/EP4653463A2/en active Pending
- 2015-08-12 US US15/329,402 patent/US11149090B2/en active Active
- 2015-08-12 CN CN202411444693.3A patent/CN119280407A/zh active Pending
- 2015-08-12 EP EP15750051.3A patent/EP3180087B1/en active Active
- 2015-08-12 WO PCT/EP2015/068598 patent/WO2016023960A1/en not_active Ceased
- 2015-08-12 JP JP2017507739A patent/JP6654187B2/ja active Active
-
2017
- 2017-02-07 PH PH12017500229A patent/PH12017500229A1/en unknown
- 2017-02-07 SV SV2017005380A patent/SV2017005380A/es unknown
- 2017-02-08 IL IL250512A patent/IL250512B/en unknown
- 2017-02-09 NI NI201700015A patent/NI201700015A/es unknown
- 2017-02-09 CL CL2017000335A patent/CL2017000335A1/es unknown
- 2017-02-10 EC ECIEPI20178984A patent/ECSP17008984A/es unknown
- 2017-02-10 CO CONC2017/0001317A patent/CO2017001317A2/es unknown
- 2017-02-15 ZA ZA2017/01126A patent/ZA201701126B/en unknown
-
2021
- 2021-09-15 US US17/475,592 patent/US20210403589A1/en not_active Abandoned
-
2023
- 2023-12-13 US US18/538,429 patent/US20240228643A9/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524715A5 (enExample) | ||
| JP2016537383A5 (enExample) | ||
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2019510733A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| WO2019086497A3 (en) | Combination therapy with targeted ox40 agonists | |
| JP2017048240A5 (enExample) | ||
| NZ752294A (en) | Cd3 binding antibodies | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| MX2018014950A (es) | Terapia de combinacion. | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2014205674A5 (enExample) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| EP3552665A3 (en) | Antibodies | |
| WO2016055432A3 (en) | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2020502271A5 (enExample) | ||
| MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. |